Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 18/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168793 | 1.00 | CXCR4 (0.54) | CXCR4MEN1USP2KMT2AL3MBTL1 | |
| SCHEMBL4170039 | 0.95 | CXCR4 (0.55) | CXCR4MEN1USP2KMT2AL3MBTL1 | |
| SCHEMBL13875229 | 0.95 | CXCR4 (0.55) | CXCR4MEN1USP2KMT2AL3MBTL1 | |
| SCHEMBL13875230 | 0.95 | CXCR4 (0.55) | CXCR4MEN1USP2KMT2AL3MBTL1 | |
| SCHEMBL4178144 | 0.94 | CXCR4 (0.54) | CXCR4MEN1USP2KMT2AL3MBTL1 | |
| SCHEMBL13875224 | 0.94 | CXCR4 (0.54) | CXCR4MEN1USP2KMT2AL3MBTL1 | |
| SCHEMBL4174681 | 0.94 | CXCR4 (0.54) | CXCR4MEN1USP2KMT2AL3MBTL1 | |
| SCHEMBL4174676 | 0.94 | CXCR4 (0.54) | CXCR4MEN1USP2KMT2AL3MBTL1 | |
| SCHEMBL4174637 | 0.92 | CXCR4 (0.58) | CXCR4MEN1USP2KMT2AL3MBTL1 | |
| SCHEMBL4168019 | 0.92 | CXCR4 (0.58) | CXCR4MEN1USP2KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093454-A1 | Chemical Compounds | SLC10A1, CYP11B2, CYP4F3 | CXCR4 2681/4885MEN1 1097/4885USP2 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.